Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

With Contact Tracing Key to Reopening the Economy, New Cloud Platform Attracting High-Profile Users

As contact tracing moves to center stage as a key to reopening the economy, HealthSpace releases a scalable cloud-based system that is rapidly being adopted, including by the state of Hawaii. HealthSpace Data Systems Ltd. (HS:CSE; HSDLF:OTCMKTS) , a Software...
Streetwise Reports | April 29, 2020 |

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses ...

Adaptimmune Shares Triple as SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications Shares of Adaptimmune Therapeutics more than tripled in value after the company reported that its SPEAR T-cell platform delivered positive initial responses in...
Streetwise Reports | January 14, 2020 |

Ovid Therapeutics Posts Positive Data from Phase 2 Seizure Reduction Trial

Ovid Therapeutics' shares are trading 25% higher today after the company reported positive initial data from its ENDYMION soticlestat phase 2 trial for patients with developmental and epileptic encephalopathies. Shares of Ovid Therapeutics Inc. (OVID:NASDAQ) are tra...
Streetwise Reports | September 25, 2019 |

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
Streetwise Reports | September 30, 2019 |

Proteostasis Therapeutics Reports Positive Results from European Cystic Fibrosis Research

Proteostasis Therapeutics' shares traded higher today after the company reported positive results in its European Cystic Fibrosis study of organoids grown from human stem cells. The firm believes the ongoing ex-vivo study supports initiation of a human clinical trial in mid-20...
Streetwise Reports | December 12, 2019 |

GenMark Shares Trade 30% Higher on Yearly Earnings and Increased SARS-CoV-2 Virus Detection Test ...

GenMark Shares Trade 30% Higher on Yearly Earnings and Increased SARS-CoV-2 Virus Detection Test Kit Shipments Shares of GenMark Diagnostics traded higher after the firm reported FY/19 financial results and announced that it has increased global shipment of i...
Streetwise Reports | March 4, 2020 |

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. Clinical-stage biotechnology company Allogene Therapeutics Inc. (ALLO:NAS...
Streetwise Reports | May 15, 2020 |

T2 Biosystems Receives BARDA Contract to Fight Antimicrobial Resistance, Shares Up More than 88%

This healthcare diagnostics stock rose more than 88% on Wednesday following the award of a BARDA contract that could be worth up to $69 million. On Wednesday morning, T2 BioSystems Inc. (TTOO:NASDAQ) announced receipt of funding from the U.S. Department of Health a...
Streetwise Reports | September 12, 2019 |

PhaseBio Shares Are on a Tear After Reporting Phase 2a Trial Results

The clinical-stage biopharmaceutical stock surged more than 30% Wednesday following a report that PB2452 caused immediate and sustained reversal of ticagrelor in older and elderly subjects. In a press release issued September 24, PhaseBio Pharmaceuticals Inc. (PHAS...
Streetwise Reports | September 26, 2019 |

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

People around the world are worried about the extent of the consequences associated with the spread of the corona virus COVID-19, and politicians and the economy are called upon to deal with the situation appropriately so that the loss of life and financial damage to the citiz...
Mario Hose | March 19, 2020 |
1 2 3 4 5 6 7 8 9 10 ...